Abstracts tagged "psoriasis and psoriatic arthritis"

Abstract Number: 673 • 2015 ACR/ARHP Annual Meeting
Characterization of Psoriatic Arthritis [Psa] in a Large, Integrated Health Plan: Demographics, Referral Patterns and Care Management
Vibeke Strand¹, Melody Chin², Arijit Ganguli³, Ridhima Nerlekar⁴, Victoria Kelly⁵, Daniel Chin⁶ and Alice Pressman⁴, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²University of California, San Francisco, San Francisco, CA, ³AbbVie Inc., North Chicago, IL, ⁴Research, Development, and Dissemination, Sutter Health, Walnut Creek, CA, ⁵Rheumatology, Palo Alto Medical Foundation, Palo Alto, CA, ⁶Clinical Evidence and Outcomes, AbbVie, North Chicago, IL
Background/Purpose: Despite guidelines and evidence indicating that early diagnosis and treatment of PsA is critical, few studies have described referral and care-management patterns in a…
Abstract Number: 1242 • 2015 ACR/ARHP Annual Meeting
Germ Line DNA Methylation Profiling Provides Novel Insights into the Parent-of-Origin Effect in Psoriatic Disease
Remy Pollock¹, Darren O'Reilly², Proton Rahman³, Vinod Chandran⁴ and Dafna Gladman⁴, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Memorial University of Newfoundland, St. John's, NF, Canada, ³Computer Sciences, Memorial University of Newfoundland, St. John's, NF, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Parent-of-origin effects refer to the differential risk or pathogenicity of a disease that depends on the sex of the disease-transmitting parent. Excessive paternal transmission…
Abstract Number: 1692 • 2015 ACR/ARHP Annual Meeting
Serious Infections in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Christopher T. Ritchlin¹, Alice B. Gottlieb², Alan Menter³, Philip J. Mease⁴, Sunil Kalia⁵, Francisco Kerdel⁶, Shelly Kafka⁷, G James Morgan⁷, Wayne Langholff⁸, Steve Fakharzadeh⁷ and Kavitha Goyal⁷, ¹Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ²Tufts Medical Center and Tufts University School of Medicine, Boston, MA, ³Baylor University Medical Center, Dallsa, TX, ⁴Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶University of Miami, Miami, FL, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, ⁸Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: To describe the rates of serious infections in psoriasis patients with psoriatic arthritis(PsA) from PSOLAR. Methods: PSOLAR is an international, disease-based, observational study in…
Abstract Number: 1694 • 2015 ACR/ARHP Annual Meeting
All-Cause Mortality and Malignancies in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Philip J. Mease¹, Alice B. Gottlieb², Alan Menter³, Christopher T. Ritchlin⁴, Sunil Kalia⁵, Francisco Kerdel⁶, Shelly Kafka⁷, James Morgan⁷, Wayne Langholff⁸, Steve Fakharzadeh⁷ and Kavitha Goyal⁷, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Tufts Medical Center and Tufts University School of Medicine, Boston, MA, ³Baylor Research Institute, Dallas, TX, ⁴Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶University of Miami, Miami, FL, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, ⁸Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Describe characteristics and incidence rates of all-cause mortality and malignancies (excluding NMSC) in psoriasis pts with psoriatic arthritis (PsA) from PSOLAR. Methods: PSOLAR is…
Abstract Number: 1716 • 2015 ACR/ARHP Annual Meeting
Prevalence of Joint Symptoms and Frequency of Joint Exams for Patients with Plaque Psoriasis without Confirmed Psoriatic Arthritis: A US Analysis
Tatiana Makhinova¹, Robert Wood², Derek Tang³, James Piercy², Steve Lobosco⁴, Bradley S. Stolshek⁵ and David J. Harrison⁵, ¹College of Pharmacy, University of Texas at Austin, Austin, TX, ²Adelphi Real World, Macclesfield, United Kingdom, ³Amgen, Inc., Thousand Oaks, CA, ⁴Adelphi Real World Ltd., Macclesfield, United Kingdom, ⁵Amgen Inc., Thousand Oaks, CA
Background/Purpose: Due to the high prevalence of PsA among patients with PsO,1 rheumatologists and dermatologists should recognize early signs and symptoms of joint involvement among…
Abstract Number: 2144 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Different Dose Regimens of a Selective IL-23p19 Inhibitor (BI 655066) Compared with Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis with and without Psoriatic Arthritis
Kim Papp¹, Alan Menter², Howard Sofen³, Stephen Tyring⁴, Jean-Philippe Lacour⁵, Beate Berner⁶, Nathan Bennett⁷, Stella Aslanyan⁷, Mary Flack⁷ and Paul Scholl⁷, ¹Probity Clinical Research, Waterloo, ON, Canada, ²Baylor Research Institute, Dallas, TX, ³Dermatology Research Associates, Los Angeles, CA, ⁴Center for Clinical Studies, Houston, TX, ⁵Dermatology Department, Hôpital de L’Archet, Nice, France, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, ⁷Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT
Background/Purpose: IL-23 is essential for the differentiation and maintenance of Th17 cells in psoriasis and psoriatic arthritis (PsA). We assessed the efficacy and safety of…
Abstract Number: 2519 • 2015 ACR/ARHP Annual Meeting
Pregnancy in Psoriatic Arthritis: A Case Series
Maria Mouyis¹, Clare Thornton¹, David Williams^2,3 and Ian Giles⁴, ¹Rheumatology, University College London Hospital, London, United Kingdom, ²Institute for Women’s Health, University College London, London, United Kingdom, ³University College London, London, United Kingdom, ⁴Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom
Background/Purpose: It is recognised that active disease in women with inflammatory arthritis is associated with adverse pregnancy outcomes. Most studies however, have focussed upon patients…
Abstract Number: 2844 • 2015 ACR/ARHP Annual Meeting
Secukinumab Reduces the Burden of Nail and Skin Disease in Patients with Psoriasis and Patients with Psoriatic Arthritis: Results from Two Phase 3 Studies
Alice B. Gottlieb¹, Kristian Reich², Zailong Wang³, Marina Milutinovic⁴ and Shephard Mpofu⁴, ¹Dermatology, Tufts Medical Center, Boston, MA, ²Dermatologikum Hamburg and Georg-August-University Göttingen, Hamburg, Germany, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Nail psoriasis is associated with decreased finger mobility and pain in patients (pts) with moderate to severe plaque psoriasis and psoriatic arthritis (PsA).1,2 Secukinumab,…
Abstract Number: 1546 • 2014 ACR/ARHP Annual Meeting
Risk of Non Melanoma Skin Cancer Among Medicare Psoriasis/Psoriasis Arthritis Patients
Huifeng Yun¹, Kevin L. Winthrop², Lang Chen³, Wilson Smith⁴, Benjamin Chan⁵, Fenglong Xie⁶, Allison Taylor⁴, Ronac Mamtani⁷, Frank I Scott⁷, James D. Lewis⁸ and Jeffrey R. Curtis⁹, ¹Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ²Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Oregon Health and Science University, Portland, OR, ⁶Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁹University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Many systemic treatments for psoriatic arthritis and psoriasis (PsA/PsO) are immune-modulating, which may increase the risk of non-melanoma skin cancer (NMSC). However, the comparative…
Abstract Number: 1562 • 2014 ACR/ARHP Annual Meeting
Psoriasis Longitudinal Assessment and Registry: Global Update upon Full Enrollment
Bruce Strober¹, Alan Menter², Craig Leonardi³, Lyn Guenther⁴, Kavitha Goyal⁵, Wayne Langholff⁶, Steve Calabro⁵ and Steve Fakharzadeh⁷, ¹University of Connecticut Heatlh Center, Farmington, CT, ²Baylor Research Institute, Dallas, TX, ³Central Dermatology, St. Louis, MO, ⁴The Guenther Dermatology Research Centre, London, ON, Canada, ⁵Janssen Services, LLC, Horsham, PA, ⁶Janssen Research and Development, LLC, Spring House, PA, ⁷Janssen Services, LLC, Spring House, PA
Background/Purpose To report the baseline demographics and clinical characteristics of participants enrolled in the Psoriasis Longtitudinal Assessment and Registry (PSOLAR) study. Methods PSOLAR is a…
Abstract Number: 1184 • 2014 ACR/ARHP Annual Meeting
Subclinical Inflammation in Psoriatic Patients with No History of Psoriatic Arthritis: An Assessment By Magnetic Resonance Imaging
David Simon¹, Francesca Faustini¹, Matthias Englbrecht¹, Arnd Kleyer¹, Roland Kocijan², Judith Haschka³, Sebastian Kraus³, Axel J. Hueber¹, Michael Sticherling⁴, Georg Schett¹ and Jürgen Rech³, ¹Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ²Medical Department II, St. Vincent Hospital, Vienna, Austria, ³Internal Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Department of Dermatology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose Six to 39% of patients with cutaneous psoriasis (PSO) can develop psoriatic arthritis (PsA). The transition from skin disease to joint involvement is only…
Abstract Number: 631 • 2014 ACR/ARHP Annual Meeting
Joint and Bone Related Pathways Discriminate Psoriatic Arthritis Lesional Skin from Psoriasis vulgaris Lesional Skin
Jennifer Belasco¹, James S. Louie², Nicholas Gulati¹, Nathan Wei³, Kristine Nograles⁴, Hiroshi Mitsui¹, Mayte Suarez-Farinas¹ and James G. Krueger¹, ¹Krueger Laboratory, The Rockefeller University, New York, NY, ²Rheumatology, UCLA School of Medicine, Los Angeles, CA, ³Arthritis & Osteoporosis Center of MD, Frederick, MD, ⁴The Rockefeller University, New York, NY
Background/Purpose: It is preferable to start therapy as early as possible in psoriatic arthritis (PsA) because of the destructive nature of the arthritis. Starting treatment…
Abstract Number: 630 • 2014 ACR/ARHP Annual Meeting
Biomarkers of Bone Remodeling Are Elevated in Psoriatic Arthritis
Fatima Abji¹, Arane Thavaneswaran¹, Vinod Chandran^1,2 and Dafna D. Gladman^1,3, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada, ³Toronto Western Research Institute, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis that develops in about a third of patients with cutaneous psoriasis (PsC). The identification of biomarkers to…
Abstract Number: 625 • 2014 ACR/ARHP Annual Meeting
Fine-Mapping Major Histocompatibility Complex Associations Identified Contribution of Multiple Class I and II HLA Genes on Risk of Psoriasis and Its Clinical Subtypes
Yukinori Okada¹, Buhm Han², Lam C. Tsoi³, Philip E. Stuart⁴, Eva Ellinghaus⁵, Trilokraj Tejasvi⁶, Vinod Chandran⁷, Fawnda Pellett⁸, Remy Pollock⁹, Anne M. Bowcock¹⁰, Gerald G. Krueger¹¹, Michael Weichenthal⁵, John J. Voorhees⁶, Proton Rahman¹², Peter K. Gregersen¹³, Andre Franke¹⁴, Rajan P. Nair⁶, Gonçalo R. Abecasis¹⁵, Dafna D. Gladman⁷, James T. Elder⁶, Paul IW. de Bakker¹⁶ and Soumya Raychaudhuri¹⁷, ¹Department of Human Genetics and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ²Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, ³Department of Biostatistics, Center for Statistical Genetics, University of Michigan, Ann Arbor, MI, ⁴Department of Dermatology, University of Michigan Medical School, Ann Arbor, MI, ⁵Christian-Albrechts-University of Kiel, Kiel, Germany, ⁶University of Michigan Medical School, Ann Arbor, MI, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹Rheumatology, University of Toronto, Toronto, ON, Canada, ¹⁰Imperial College, London, United Kingdom, ¹¹Dermatology, University of Utah, Salt Lake City, UT, ¹²Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ¹³The Feinstein Institute for Medical Research, Manhasset, NY, ¹⁴Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany, ¹⁵University of Michigan, Ann Arbor, MI, ¹⁶University Medical Center, Utrecht, Netherlands, ¹⁷Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Psoriasis vulgaris (PsV) risk is strongly associated with genetic variation within the major histocompatibility complex (MHC) region, although its fine genetic architecture has not…
Abstract Number: 57 • 2014 ACR/ARHP Annual Meeting
Risk of Hospitalized Infection in a Psoriasis/Psoriatic Arthritis Cohort
Kevin L. Winthrop¹, Lang Chen², John Baddley², Allison Taylor³, Benjamin Chan⁴, Huifeng Yun⁵, Sarah Siegel⁶ and Jeffrey R. Curtis⁷, ¹Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ²Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Oregon Health and Science University, Portland, OR, ⁵Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ⁶Oregon Health & Science University, Portland, OR, ⁷The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Psoriasis (PsO)/Psoriatic arthritis (PsA) often requires treatment with systemic immunosuppressive agents, some of which may increase hospitalized infection risk. Few population-based studies to date…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].